Health  Vol.5 No.10 , October 2013
Synergy in antibacterial activities of Ampicillin trihydrate, stabilized with a synthetic aluminum-magnesium silicate and immune-stimulants, on resistant Escherichia coli infection
ABSTRACT
To treat resistant Escherichia coli infection in chicks, Ampicillin was stabilized with a synthetic aluminum-magnesium silicate (AMS) to prolong its bioavailability. Its dose was also reduced to minimize adverse side effects. Vitamins A, C, E and Selenium levels in the chicks’ feeds were increased to enhance immune response of the chicks. E. coli coloning forming units, per ml of bile of the chicks, treated with Ampicillin and with Ampicillin in AMS, were: 228800.00 ± 90103.50 and 134500.00 ± 44937.97 at 10 mg/kg, 104400.00 ± 36024.44 and 34800.00 ± 8014.97 at 7.5 mg/kg, 198400.00 ± 129301.80 and 156800.00 ± 109392.70 at 5 mg/kg. Mean bacterial loads of the untreated groups, fed normal feed and those fed the fortified feed were 824400.00 ± 322424.80 and 534800.00 ± 277832.80. At 7.5 mg/kg. Ampicillin in the AMS, effectively (P < 0.05) treated resistant E. coli infection in chicks, fed immune-stimulants, with the infection rate reduced by 95.8%.

Cite this paper
Ezeibe, M. , Ezeobele, O. , Esen, M. , Ngene, A. , Mbuko, I. , Chukwudi, I. , Omoja, V. and Ezeh, I. (2013) Synergy in antibacterial activities of Ampicillin trihydrate, stabilized with a synthetic aluminum-magnesium silicate and immune-stimulants, on resistant Escherichia coli infection. Health, 5, 1548-1552. doi: 10.4236/health.2013.510210.
References
[1]   NTP (1987) Abstract for Tr-318-Ampicillin Trihydrate (CASRN 7177-48-2) toxicology and carcinogenesis stu dies of Ampicillin Trihydrate (CAS No. 7177-48-2) in F344/N Rats and 36C 3F, Mice (Gavage studies). NTP Study Reports, National Toxicological Program, USA Government.

[2]   Ewers, C., Anto, E.M., Diehi, I., Philip, H.C. and Wieler, L.H. (2004) Molecular epidemiology of Avian pathogenic Escherichia coli isolated from colisepticaemia in poultry. Veterinary Microbiology, 104, 91-101. http://dx.doi.org/10.1016/j.vetmic.2004.09.008

[3]   Johnson, J.R., Sannes, M.R., Croy, C., Johnson, B., Clabots, C., Kustowski, M.A., Bender, J., Smith, K.E., Winokur, P.L. and Belongia, E.A. (2007) Antimicrobial drugresistant Esherichia coli from human and poultry products Minnesota and Wisconsin. Emerging Infectious Diseases, 13, 1576-1585. http://dx.doi.org/10.3201/eid1306.061576

[4]   Butaye, P. and Jasson, V. (2000) E. coli infections. CODACERVA Publications. www.coda-cerva.com

[5]   Murray, P.R. (2007) Mannual of clinical microbiology. 9th Edition, ASM Press, Washington DC.

[6]   Diarra, M.S., Silversides, F.G., Diarrasouba, F., Pritchard, J., Masson, L., Brouseau, R., Bonnet, C., Delaquis, P., Bach, S., Skura, B.J. and Topp, E. (2007) Impact of food supplementation with antimicrobial agents on growth performance of broiler chickens, Clostridium perfringes and enterococcus counts and antibiotic resistance phenotypes and distribution of antimicrobial resistance determinants in Escherichia coli isolates. Environmental Microbiology, 73, 6566-6576. http://dx.doi.org/10.1128/AEM.01086-07

[7]   McMullin, P. (2004) Poultry disease. www.poultrysite.com

[8]   Majowicz, S.E., Musto, J., Scallan, E., Angulo, F.J., Kir, K.M., O-Brien, S.J., Jones, T.F., Fazil, A. and Hoekkstra, R.M. (2010) The global burden of collibacillosis. Clinical Infectious Diseases, 50, 882-889. http://dx.doi.org/10.1086/650733

[9]   Shane, S.M. (2009) Reducing pathogenic E. coli infection by vaccination. World Poultry, 25, 21-23.

[10]   Gunderson, B.W., Ross, G.H., Ibrahim, K.H. and Rotschafer, J.C. (2001) What do we really know about antibiotics. Pharmacodynamics? Pharmacotherapy, 21, 302S-318S. http://dx.doi.org/10.1592/phco.21.18.302S.33905

[11]   Aiello, S.E. (1998) Merck veterinary manual. 8th Edition, Merk and Co. Inc., Whitehouse Station.

[12]   Wai, K.-N., Dekay, H.G. and Banker, G.S. (1996). Application of montmorrillonitse in tablet making. Journal of Pharmaceutical Sciences, 55, 1244-1248. http://dx.doi.org/10.1002/jps.2600551116

[13]   Vanderbilt, T.I. (1992). Veegum—The versatile ingredient for pharmaceutical formulations. Technical Literature, RT Vanderbilt Co., Inc., New York.

[14]   Cristina, E., Ivan, P. and Kevin, R. (2007) Nanomaterials and nanoparticles: Sources and toxicity. Biointerphases, 2, MR17-MR71.

[15]   Schills, S. (2002) The use of clay in fight against effect of ammonia.
http://www.mistalus.net

[16]   Elmore, A.R. (2003) Cosmetics ingredients review experts panel’s report. International Journal of Toxicology, 22, 37-102.

[17]   Ezeibe, M.C.O. (2006) Admacine. Federal Republic of Nigeria. Patents and Design Act. Cap. 344. LDN. 1990.

[18]   Ezeibe, M.C.O., Mbuko, I.J., Okoroafor, O.N., Okonkwo, A.C., Animoke, P.C., Orajaka, L.J.E. and Ngene, A.A. (2009) In vitro and in vivo effects of Aluminium-Magnesium Silicate on Infectious Bursal Disease virus in chikens. Animal Science Papers and Reports, 3, 132.

[19]   Ezeibe, M.C.O., Nwaogu, I.C., Nwaigwe, A.N., Okoroafor, O.N., Eze, J.I. and Ngene, A.A. (2010) Aluminium-Magnesium Silicate inhibits canine parvovirus and cures infected dogs. Health, 2, 1215-1217. http://dx.doi.org/10.4236/health.2010.210179

[20]   Ezeibe, M.C.O., Okafor, U.C., Okoroafor, O.N., Eze, J.I., Ngene, A.A., Animoke, P.C. and Mbuko, I.J. (2011) Effect of Aluminium-Magnesium Silicate on anticcocidial activity of sulphadimidine. Tropical Veterinarian, 29, 41-44.

[21]   Ezeibe, M.C.O., Ijabo, O., Uzopuo, C., Okoroafor, O.N., Eze, J.I., Mbuko, I.J., Sanda, M.E., Animoke, P.C. and Ngene, A.A. (2011) Effects of Aluminium-Magnesium Silicate on Newcastle disease virus and on recovery of infected chicks. International Journal of Biological and Chemical Sciences, 5, 825-829.

[22]   Ezeibe, M.C.O., Elendu-Eleke, N.P., Okoroafor, O.N. and Ngene, A.A. (2012) Adjuvant effect of a synthetic Aluminium-Magnesium Silicate on chloroquine phosphate, against Plasmodium berghei. Health, 4, 448-451. http://dx.doi.org/10.4236/health.2012.48071

[23]   Ezeibe, M.C.O., Anosa, G.N., Okorie, O.K., Elendu-Eleke, N.P., Okoroafor, O.N., Ngene, A.A. and Chikelu, O.N. (2012) Aluminium-Magnesium Silicate enhances antibacterial activity of Ampicillin trihydrate, against S. gallinarum. Health, 4, 675-678.
http://dx.doi.org/10.4236/health.2012.49106

[24]   Ezeibe, M.C.O., Dire, C.D., Anosa, G.N., Chikelu, O.N., Okoroafor, O.N., Okorie, O.K., Ngene, A.A., Idika, I.K., Ogunniran, T.M. and Ezeala, I.E. (2012) Efficacy of piperazine citrate, stabilized with Aluminium-Magnesium Silicate, against Helignosomoides bakeri. Health, 4, 890-892. http://dx.doi.org/10.4236/health.2012.410135

[25]   Ezeibe, M.C.O., Chima, U.M., Ngene, A.A., Okoroafor, O.N., Kalu, I.I. and Esen, M.E. (2012) Effective treatment of resistant Escherichia coli infection, with sulphadimidine stabilized in a synthetic Aluminium-Magnesium Silicate. Health, 4, 1295-1298. http://dx.doi.org/10.4236/health.2012.412190

[26]   National Research Council (1994) Nutrient requirements of poultry. 9th Edition, National Academy Press, Washington DC.

[27]   Brent, W., Gunderson, Gigi, H., Ross, K.H.I. and John, C.R. (2001) What do we really know about antibiotics pharmacodynamics? Pharmacotherapy, 21, 28-31.

[28]   Kaplan, R.M. (2002) Anthelmintic resistance in nematods of horses. Veterinary Research, 33, 491-507. http://dx.doi.org/10.1051/vetres:2002035

 
 
Top